Search Results - "Argiles Martínez, G."

Early interventions to detect potential drug–drug interactions on patient eligibility for phase 1 clinical trials by Azaro, A, Ghiglione, L, Valdivia, C, Munné, M, Renedo, B, Sabaté, N, Alcalde, M, Braña, I, Hierro, C, Martin-Liberal, J, Ochoa de Olza, M, Argiles Martínez, G, Vilaró, M, Tabernero, J, Rodon, J

“…An abstract of a study by Azaro et al determining the potential drug-drug interactions (DDI) on patient eligibility for phase 1 clinical trials is presented…”
Get full text

Safety run-in evaluation of the phase I trial of trifluridine/tipiracil (FTD/TPI) in combination with oxaliplatin and a monoclonal antibody (bevacizumab or nivolumab) in patients (pts) with metastatic colorectal cancer (mCRC) by Calvo Ferrandiz, A, Dahan, L, Hollebecque, A, Prager, G, Andre, T, Argiles Martinez, G, Bordonaro, R, Stein, A, Tortora, G, Leger, C, Amellal, N, Tabernero, J

Get full text

108 - Early interventions to detect potential drug–drug interactions on patient eligibility for phase 1 clinical trials by Azaro, A., Ghiglione, L., Valdivia, C., Munné, M., Renedo, B., Sabaté, N., Alcalde, M., Braña, I., Hierro, C., Martin-Liberal, J., Ochoa de Olza, M., Argiles Martínez, G., Vilaró, M., Tabernero, J., Rodon, J.

Get full text

499P Heterogeneity in the immune inflamed biomarkers of MSS and MSI colorectal cancer by Argota, I. Baraibar, Rubio-Pérez, C., Martinez, G. Argiles, Montañá, F.J. Ros, Salvà, F., Margalef, N. Mulet, Urteaga, J.L. Cuadra, Castaneda, D.H. Marmolejo, Gonzalez, N. Saoudi, Ciardiello, D., Tabernero, J., Seoane, J., Elez, E.

Get full text

426P Spotlight on refractory metastatic colorectal cancer (refMCRC): Role of prognostic characteristics in the continuum of care by Valdivia, A.A., Salva, F., Ros, J., Baraibar, I., Argiles Martinez, G., Saoudi Gonzalez, N., Garcia, A., Mulet Margalef, N., Cuadra Urteaga, J.L., Capdevila, J., Salud Salvia, M.A., Paez, D., Casado, E., Comas, R., Ruiz-Pace, F., Villacampa Javierre, G., Acosta Eyzaguirre, D.A., Dienstmann, R., Elez Fernandez, M.E., Tabernero, J.

Get full text

470PSafety run-in evaluation of the phase I trial of trifluridine/tipiracil (FTD/TPI) in combination with oxaliplatin and a monoclonal antibody (bevacizumab or nivolumab) in patients (pts) with metastatic colorectal cancer (mCRC) by Calvo Ferrandiz, A, Dahan, L, Hollebecque, A, Prager, G, Andre, T, Argiles Martinez, G, Bordonaro, R, Stein, A, Tortora, G, Leger, C, Amellal, N, Tabernero, J

Get full text

531MO VHIO immune gene-expression signature (VIGex) to enrich patient selection in immunotherapy (IT) phase I clinical trials by Hernando-Calvo, A., Mancuso, F.M., Braña, I., Santa Gadea, O. Saavedra, Vieito, M., Casal, G. Alonso, Galvao de Aguiar, V., Pedrazzoli, A.B. Azaro, Matos, I., Berché, R., Worham, N. Ann, Saura, C., Martinez, G. Argiles, Elez, E., Couselo, E. Munoz, Felip, E., Seoane, J., Tabernero, J., Vivancos, A., Garralda, E.

Get full text

572P Limited efficacy of immunotherapy combination regimens in patients with unselected “cold” tumours enrolled in early clinical trials by Santa Gadea, O. Saavedra, Hernando-Calvo, A., Berché, R., Matos, I., Gardeazabal, I., Pedrazzoli, A.B. Azaro, Villar, M. Vieito, Braña, I., Casal, G. Alonso, Galvao de Aguiar, V., Pedrola, A., Martinez, G. Argiles, Mercadé, T. Macarulla, Capdevila, J., Cedres, S., Oaknin, A., Elez, E., Tabernero, J., Dienstmann, R., Garralda, E.

Get full text

487P Use of patient-derived tumour organoids to identify acquired treatment resistance and determine optimal post-progression combinations in metastatic colorectal cancer by Martini, G., Borreil, I. Puig, Ramirez, L., Chicote, I., Mancuso, F.M., Caratu, G., Serres-Créixams, X., Fasani, R., Jimenez, J., Montañá, F.J. Ros, Argota, I. Baraibar, Ciardiello, D., Margalef, N. Mulet, Dienstmann, R., Vivancos, A., Elez, E., Palmer, H., Tabernero, J., Martinez, G. Argiles

Get full text

3O VHIO immune gene-expression signature (VIGex) to enrich patient selection in immunotherapy phase I clinical trials by Hernando, A., Mancuso, F.M., Braña, I., Saavedra, O., Vieito Villar, M., Gardeazabal Gonzalez, I., Alonso Casal, G., Galvao, V., Azaro Pedrazzoli, A.B., Matos Garcia, I., Berche, R., Wornham, N.A., Saura Manich, C., Argiles Martinez, G., Élez, E., Munoz Couselo, E., Felip, E., Tabernero, J., Vivancos, A., Garralda, E.

Get full text

121P - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) by Cardone, C., Blauensteiner, B., Moreno-Viedma, V., Vitiello, P.P., Martini, G., Ciardiello, D., Simeon, V., Rachiglio, A.M., Rizzi, D., Maiello, E., Latiano, T., Cremolini, C., Argiles Martinez, G., Elez, E., Falcone, A., Tabernero, J., Normanno, N., Sibilia, M., Ciardiello, F., Martinelli, E.

“…Activation of AXL receptor tyrosine kinase is a key mediator of epithelial to mesenchymal transition (EMT). AXL is overexpressed in several human cancers,…”
Get full text

575P - RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first-line treatment in metastatic colorectal cancer by Martini, G., Elez, E., Mancuso, F.M., España, M A Gomez, Caratù, G., Matito, J., Martinez, G Argiles, Margalef, N Mulet, Morales, M J Ortiz, Montana, F J Ros, Garcia, A., Comas, R., Vivas, C Santos, Perez-Lopez, R., Nuciforo, P.G., Casanovas, O., Dienstmann, R., Tabernero, J., Aguilar, E Aranda, Vivancos, A.

“…So far, no biomarkers of response to anti-angiogenic drugs are available in colorectal cancer (CRC) treatment. Liquid biopsy technique identifies actionable…”
Get full text

575PRAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first-line treatment in metastatic colorectal cancer by Martini, G, Elez, E, Mancuso, F M, España, M A Gomez, Caratù, G, Matito, J, Martinez, G Argiles, Margalef, N Mulet, Morales, M J Ortiz, Montana, F J Ros, Garcia, A, Comas, R, Vivas, C Santos, Perez-Lopez, R, Nuciforo, P G, Casanovas, O, Dienstmann, R, Tabernero, J, Aguilar, E Aranda, Vivancos, A

“…Abstract Background So far, no biomarkers of response to anti-angiogenic drugs are available in colorectal cancer (CRC) treatment. Liquid biopsy technique…”
Get full text

AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) by Cardone, C., Blauensteiner, B., Moreno-Viedma, V., Vitiello, P.P., Martini, G., Ciardiello, D., Simeon, V., Rachiglio, A.M., Rizzi, D., Maiello, E., Latiano, T., Cremolini, C., Argiles Martinez, G., Elez, E., Falcone, A., Tabernero, J., Normanno, N., Sibilia, M., Ciardiello, F., Martinelli, E.

Get full text

RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first-line treatment in metastatic colorectal cancer by Martini, G., Elez, E., Mancuso, F.M., España, M A Gomez, Caratù, G., Matito, J., Martinez, G Argiles, Margalef, N Mulet, Morales, M J Ortiz, Montana, F J Ros, Garcia, A., Comas, R., Vivas, C Santos, Perez-Lopez, R., Nuciforo, P.G., Casanovas, O., Dienstmann, R., Tabernero, J., Aguilar, E Aranda, Vivancos, A.

Get full text

121PAXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) by Cardone, C, Blauensteiner, B, Moreno-Viedma, V, Vitiello, P P, Martini, G, Ciardiello, D, Simeon, V, Rachiglio, A M, Rizzi, D, Maiello, E, Latiano, T, Cremolini, C, Argiles Martinez, G, Elez, E, Falcone, A, Tabernero, J, Normanno, N, Sibilia, M, Ciardiello, F, Martinelli, E

“…Abstract Background Activation of AXL receptor tyrosine kinase is a key mediator of epithelial to mesenchymal transition (EMT). AXL is overexpressed in several…”
Get full text

Molecular, clinical and prognostic characterization of double KRAS/PIK3CA (dKP) mutated metastatic colorectal cancer (mCRC) by Grasselli, J., Elez, E., Martinez, G. Argiles, Sanz-Garcia, E., Macarulla, T., Capdevila, J., Alsina, M., Sauri, T., Hierro, C., Verdaguer, H., Matos, I., Garcia, A., Nuciforo, P., Landolfi, S., Palmer, H. Garcia, Dienstmann, R., Vivancos, A., Tabernero, J.

Get full text

Prognostic impact of KRAS mutation in metastatic (met) pancreatic cancer patients (pts) by Verdaguer, H., Sauri, T., Ruiz, F., Vivancos, A., Nuciforo, P., Capdevila, J., Elez, E., Alsina, M., Martinez, G. Argiles, Hierro, C., Grasselli, J., Matos, I., Tabernero, J., Dienstmann, R., Macarulla, T.

Get full text

Genotyping circulating tumor DNA identifies metastatic colorectal cancer (mCRC) patients highly sensitive to Sym004 by Montagut Viladot, C., Bardelli, A., Tuxen Poulsen, T., Dienstmann, R., Kragh, M., Kopetz, S., Koefoed, K., Ciardiello, F., Ding, C., Vidal, J., Clausell-Tormos, J., Siravegna, G., Lindsted, T., Pedersen, M.W., Rospo, G., Argilés Martinez, G., Nadler, P., Horak, I.D., Tabernero, J.

Get full text

A randomized Phase 2 study comparing different dosing approaches of induction treatment (first cycle) of regorafenib in metastatic colorectal cancer (mCRC) patients by Argilés Martinez, G., Sanz-Garcia, E., Valladares-Ayerbes, M., Viéitez, J.M., Garcia-Alfonso, P., Gravalos, C., Tobeña, M., Duran Ogaya, G., Cano Osuna, M.T., García-Paredes, B., Santos, C., Rodríguez-Garrote, M., Rivera Herrero, F., Safont, M.J., Falcone, A., Ciardiello, F., Goldberg, R., Bennouna, J., Tabernero, J., Aranda Aguilar, E.

Get full text